2008
DOI: 10.1200/jco.2008.26.15_suppl.10547
|View full text |Cite
|
Sign up to set email alerts
|

Phase II clinical trial of imatinib mesylate in therapy of KIT and/or PDGF-Rα-expressing Ewing sarcoma family of tumors (ESFT) and desmoplastic small round cell tumors (DSRCT)

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
43
0

Year Published

2012
2012
2020
2020

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 31 publications
(43 citation statements)
references
References 0 publications
0
43
0
Order By: Relevance
“…Phase I studies using anti-ILG R1, trabectedin, tyrosine kinase inhibitors, ganitumab, temsirolimus alone, and temsirolimus combined with cixutumumab (a fully human IgG1 monoclonal antibody directed against insulin growth factor 1 receptor, IGF-1R) have reported interesting results in this disease. [25][26][27][28][29][30] On the basis of our results, patients should receive induction chemotherapy because it may select the best candidates for surgery and improve rates of complete resection. A radiologic response was observed in 68 % of our patients.…”
Section: Discussionmentioning
confidence: 92%
“…Phase I studies using anti-ILG R1, trabectedin, tyrosine kinase inhibitors, ganitumab, temsirolimus alone, and temsirolimus combined with cixutumumab (a fully human IgG1 monoclonal antibody directed against insulin growth factor 1 receptor, IGF-1R) have reported interesting results in this disease. [25][26][27][28][29][30] On the basis of our results, patients should receive induction chemotherapy because it may select the best candidates for surgery and improve rates of complete resection. A radiologic response was observed in 68 % of our patients.…”
Section: Discussionmentioning
confidence: 92%
“…Accordingly, the specific tyrosine kinase inhibitor imatinib was used to target PDGFRα and KIT in preclinical and clinical studies. Though in vitr o preclinical experiments demonstrated proof of concept, in ES the IC 50 values of imatinib (10–12 µM) markedly exceeded levels achievable in the clinic 28,29,61,62 . In a phase II study of patients with refractory or relapsed pediatric solid tumours, one (4.2%) of 24 ES patients had a PR 28 .…”
Section: Molecular Targets For Directed Therapymentioning
confidence: 97%
“…Because imatinib primarily targets PDGFRα and KIT, a high protein expression level in tumour could be considered as one criterion for trial enrollment. In another phase II clinical trial, immunohistochemical evidence of expression ≥2+/4+ for either KIT or PDGFRα was, in fact, applied as one of the required criteria for patient enrollment 29 . One (20%) out of five ES patients had a PR after eight months of treatment.…”
Section: Molecular Targets For Directed Therapymentioning
confidence: 99%
“…Moreover, EWSR1/WT1 has been proven to induce the upregulation of PDGF ligand and receptor, which might be responsible for the prominent tumor-associated desmoplasia detected in this disease [18-20]. On this bases, imatinib activity was tested in two phase II studies, showing unfortunately no efficacy in advanced DSRCT (no response reported) [21,22]. Italiano et al recently reported on their experience in advanced DSRCT patients treated with sunitinib, a multi-kinase inhibitor that blocks several tyrosine kinase receptors such as VEGF receptors, PDGF receptors, KIT, FLT3, and CSF-1.…”
Section: Introductionmentioning
confidence: 99%